Xtract One Announces Fiscal 2024 Fourth Quarter Conference Call

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) — Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) (“Xtract One” or the “Company”), a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, today announced that it will release fiscal 2024 fourth quarter results after the close of trading […]

Advent Technologies Reports Q1 2024 Results

Operational Highlights Started work on the Joint Project with Airbus to benchmark HT-PEM fuel cell MEAs in aviation. Continued work with the U.S. Department of Defense on two previously awarded contracts for portable power systems. Continued Technology Assessment Work for four of the largest 15 automotive manufacturers in the world. Continued streamlining of operations process

Premier American Uranium Completes Successful Inaugural Drill Program at the Cyclone ISR Uranium Project, Great Divide Basin, Wyoming

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) — Premier American Uranium Inc. (“PUR”, the “Company” or “Premier”) (TSXV: PUR) (OTCQB: PAUIF) is pleased to announce the successful completion of the 2024 exploration drilling program at the 100%-owned Cyclone ISR Uranium Project (“Cyclone” or the “Project“) in the Great Divide Basin, Wyoming (Figure 1). A total of

Er-Kim CEO Cem Zorlular Recognized as a Patient Champion on the 2024 PharmaVoice 100

ISTANBUL, Oct. 15, 2024 (GLOBE NEWSWIRE) — Cem Zorlular, CEO of Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, was recently recognized as a Patient Champion on this year’s PharmaVoice 100. Established in 2005, the annual list recognizes the most inspiring people across all sectors of the life sciences industry who

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Phase 2a efficacy and safety trial enrollment initiation expected in H1 2025 ~40 million Americans go to emergency department annually after a traumatic experience 1 Second externally funded stress-related trial for BXCL501 NEW HAVEN, Conn., Oct. 15, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative

Shaq-a-Roni Returns to Papa Johns, Reinforcing Its Commitment to Better

EDMONTON, Alberta, Oct. 15, 2024 (GLOBE NEWSWIRE) — Papa Johns is proud to announce the return of its popular Shaq-a-Roni pizza across Canada for its 5th consecutive year. Crafted in partnership with former basketball superstar and Papa Johns franchisee, Shaquille O’Neal, the Shaq-a-Roni feeds a big appetite for big impact. For every Shaq-a-Roni sold between

TransPerfect’s GlobalLink Named Leading Localization Platform in G2 Fall 2024 Report

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) — TransPerfect, the world’s largest provider of language and AI solutions for global business, announced that its GlobalLink(R) platform has been recognized as a Leading Enterprise Translation Management Software and Enterprise Website Translation Tool in the G2 Fall 2024 Report. GlobalLink’s recognition reflects feedback from real users who

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna Therapeutics Corp. (TSX: MDNA; OTCQX: MDNAF), a clinical-stage immunotherapy company, has qualified to trade on the OTCQX(R) Best Market. Medicenna Therapeutics Corp. upgraded to OTCQX from the

BiomX Announces a Mandatory Unit Separation

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces a mandatory separation of its units, which trade under the ticker symbol “PHGE.U”, each of which consists of one share of Common

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

— Topline Results Expected Q2 2025 — WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult

Scroll to Top